Patents by Inventor Rainer Machauer

Rainer Machauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives
    Publication number: 20240158399
    Abstract: The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Application
    Filed: February 15, 2023
    Publication date: May 16, 2024
    Inventors: Luca ARISTA, Christina HEBACH, Gregory John HOLLINGWORTH, Philipp HOLZER, Patricia IMBACH-WEESE, Julien LORBER, Rainer MACHAUER, Niko SCHMIEDEBERG, Anna VULPETTI, Thomas ZOLLER
  • NEW CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR COMPOUND
    Publication number: 20240116900
    Abstract: Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition can be used as a medicament, in particular for the treatment of cancer, and KRAS G12C-mutant cancer.
    Type: Application
    Filed: October 29, 2021
    Publication date: April 11, 2024
    Inventors: Simona COTESTA, Heng GE, Marc GERSPACHER, Catherine LEBLANC, Bo LIU, Edwige Liliane Jeanne LORTHIOIS, Rainer MACHAUER, Robert MAH, Tanja MEISTER, Christophe MURA, Pascal RIGOLLIER, Nadine SCHNEIDER, Stefan STUTZ, Andrea VAUPEL, Nicolas WARIN, Rainer WILCKEN, Lijun XUE, Marie-Anne LOZAC'H, Ross STRANG
  • PHARMACEUTICAL COMBINATIONS COMPRISING A KRAS G12C INHIBITOR AND USES OF A KRAS G12C INHIBITOR FOR THE TREATMENT OF CANCERS
    Publication number: 20240082218
    Abstract: It relates to a pharmaceutical combination comprising a KRAS G12C inhibitor, in particular 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro [3.3] heptan-2-yl} prop-2-en-1-one (Compound A) and one or more therapeutically active agents selected from a SHP2 inhibitor (e.g. TNO155) and a PD-1 inhibitor, pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutated.
    Type: Application
    Filed: December 20, 2021
    Publication date: March 14, 2024
    Inventors: Vasileios ASKOXYLAKIS, Saskia Maria BRACHMANN, Simona COTESTA, Xiaoming CUI, Jeffrey ENGELMAN, Anna FARAGO, Marc GERSPACHER, Diana GRAUS PORTA, Catherine LEBLANC, Edwige Liliane Jeanne LORTHIOIS, Bo LIU, Rainer MACHAUER, Robert MAH, Christophe MURA, Pascal RIGOLLIER, Nadine SCHNEIDER, Stefan STUTZ, Andrea Helga Emmi VAUPEL, Nicolas WARIN, Andreas WEISS, Rainer WILCKEN, Padmaja YERRAMILLI-RAO
  • 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives
    Publication number: 20230398117
    Abstract: The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Application
    Filed: December 1, 2022
    Publication date: December 14, 2023
    Inventors: Luca ARISTA, Christina HEBACH, Gregory John HOLLINGWORTH, Philipp HOLZER, Patricia IMBACH-WEESE, Rainer MACHAUER, Niko SCHMIEDEBERG, Anna VULPETTI, Thomas ZOLLER
  • Pyrazolyl derivatives useful as anti-cancer agents
    Patent number: 11702409
    Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: July 18, 2023
    Assignee: NOVARTIS AG
    Inventors: Simona Cotesta, Marc Gerspacher, Catherine Leblanc, Edwige Liliane Jeanne Lorthiois, Bo Liu, Rainer Machauer, Robert Mah, Christophe Mura, Pascal Rigollier, Nadine Schneider, Stefan Stutz, Andrea Vaupel, Nicolas Warin, Rainer Wilcken
  • Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors
    Patent number: 11613543
    Abstract: The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: March 28, 2023
    Assignee: NOVARTIS AG
    Inventors: Luca Arista, Christina Hebach, Gregory John Hollingworth, Philipp Holzer, Patricia Imbach-Weese, Julien Lorber, Rainer Machauer, Niko Schmiedeberg, Anna Vulpetti, Thomas Zoller
  • 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives
    Patent number: 11541056
    Abstract: The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: January 3, 2023
    Assignee: NOVARTIS AG
    Inventors: Luca Arista, Christina Hebach, Gregory John Hollingworth, Philipp Holzer, Patricia Imbach-Weese, Rainer Machauer, Niko Schmiedeberg, Anna Vulpetti, Thomas Zoller
  • Pyrazolyl derivatives useful as anti-cancer agents
    Publication number: 20220363670
    Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: December 17, 2020
    Publication date: November 17, 2022
    Inventors: Simona Cotesta, Marc Gerspacher, Catherine Leblanc, Edwige Liliane Jeanne Lorthiois, Bo Liu, Rainer Machauer, Robert Mah, Christophe Mura, Pascal Rigollier, Nadine Schneider, Stefan Stutz, Andrea Vaupel, Nicolas Warin, Rainer Wilcken
  • Aza-indazole compounds for use in tendon and/or ligament injuries
    Patent number: 11203595
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: December 21, 2021
    Assignee: NOVARTIS AG
    Inventors: Badry Bursulaya, Andreas Fisch, James Paul Lajiness, Rainer Machauer, Swapnil Malekar, Hank Michael James Petrassi, Farshad Ramazani, Anne-Catherine Remond, Thomas Ullrich, Peggy Usselmann, Eric Vangrevelinghe
  • 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives
    Publication number: 20210251996
    Abstract: The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Application
    Filed: March 25, 2019
    Publication date: August 19, 2021
    Inventors: Luca Arista, Christina Hebach, Gregory John Hollingworth, Philipp Holzer, Patricia Imbach-Weese, Rainer Machauer, Niko Schmiedeberg, Anna Vulpetti, Thomas Zoller
  • AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES
    Publication number: 20210188842
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 28, 2020
    Publication date: June 24, 2021
    Inventors: Badry BURSULAYA, Andreas FISCH, James Paul LAJINESS, Rainer MACHAUER, Swapnil MALEKAR, Hank Michael James PETRASSI, Farshad RAMAZANI, Anne-Catherine REMOND, Thomas ULLRICH, Peggy USSELMANN, Eric VANGREVELINGHE
  • N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives
    Publication number: 20210002285
    Abstract: The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 7, 2021
    Inventors: Luca Arista, Christina Hebach, Gregory John Hollingworth, Philipp Holzer, Patricia Imbach-Weese, Julien Lorber, Rainer Machauer, Niko Schmiedeberg, Anna Vulpetti, Thomas Zoller
  • Aza-indazole compounds for use in tendon and/or ligament injuries
    Patent number: 10766894
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: September 8, 2020
    Assignee: NOVARTIS AG
    Inventors: Badry Bursulaya, Andreas Fisch, James Paul Lajiness, Rainer Machauer, Swapnil Malekar, Hank Michael James Petrassi, Farshad Ramazani, Anne-Catherine Remond, Thomas Ullrich, Peggy Usselmann, Eric Vangrevelinghe
  • Heterocyclic derivatives and their use in the treatment of neurological disorders
    Patent number: 10683287
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: June 16, 2020
    Assignee: Novartis AG
    Inventors: Sangamesh Badiger, Murali Chebrolu, Konstanze Hurth, Sebastien Jacquier, Rainer Martin Lueoend, Rainer Machauer, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle
  • Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders
    Publication number: 20200048236
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Application
    Filed: April 9, 2019
    Publication date: February 13, 2020
    Inventors: Sangamesh Badiger, Murali Chebrolu, Konstanze Hurth, Sebastien Jacquier, Rainer Martin Lueoend, Rainer Machauer, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle
  • AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES
    Publication number: 20190300522
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: September 21, 2017
    Publication date: October 3, 2019
    Inventors: Badry BURSULAYA, Andreas FISCH, James Paul LAJINESS, Rainer MACHAUER, Swapnil MALEKAR, Hank Michael James PETRASSI, Farshad RAMAZANI, Anne-Catherine REMOND, Thomas ULLRICH, Peggy USSELMANN, Eric VANGREVELINGHE
  • Heterocyclic derivatives and their use in the treatment of neurological disorders
    Patent number: 10301296
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: May 28, 2019
    Assignee: Novartis AG
    Inventors: Sangamesh Badiger, Murali Chebrolu, Konstanze Hurth, Sebastien Jacquier, Rainer Martin Lueoend, Rainer Machauer, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle
  • Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders
    Publication number: 20190062319
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Application
    Filed: June 27, 2018
    Publication date: February 28, 2019
    Inventors: Sangamesh Badiger, Murali Chebrolu, Konstanze Hurth, Sebastien Jacquier, Rainer Martin Lueoend, Rainer Machauer, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle
  • Substituted indazoles for treating tendon and/or ligament injuries
    Patent number: 10112907
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: October 30, 2018
    Assignee: NOVARTIS AG
    Inventors: Badry Bursulaya, Andreas Fisch, James Paul Lajiness, Rainer Machauer, Swapnil Malekar, Hank Michael James Petrassi, Farshad Ramazani, Anne-Catherine Remond, Thomas Ullrich, Peggy Usselmann, Eric Vangrevelinghe
  • Heterocyclic derivatives and their use in the treatment of neurological disorders
    Patent number: 10035794
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: July 31, 2018
    Assignee: Novartis AG
    Inventors: Sangamesh Badiger, Murali Chebrolu, Konstanze Hurth, Sebastien Jacquier, Rainer Martin Lueoend, Rainer Machauer, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle